China Pharmaceutical Sector Report 2025 Q3

Since 2017, China has been the second largest pharmaceutical market, after the US, according to Deloitte, and at the end of 2024 it had a share of 10% of the global pharmaceutical market. According to the National Bureau of Statistics (NBS), the total operating revenue of China's pharmaceutical firms above a designated size (those with an annual revenue of RMB 20mn or above) increased by 1.16% y/y in 2024. However, the net profit of these firms registered a decline of 2.16% y/y, mainly affected by pricing pressures resulting from the increased scale of volume-based procurement (VBP).

This report provides a complete and detailed analysis of the "Healthcare and pharma" sector for China. EMIS Insights presents in-depth business intelligence in a standard format across countries and regions, providing a balanced mix between analysis and data.

What this report allows you to do:

• Understand the key elements at play in the "Healthcare and pharma" sector in China
• Crystallise the forces both driving and restraining this sector in China
• Ascertain China’s position in the global sector
• Build a complete perspective on sector trade, investment and employment
• Understand the competitive landscape and who the major players are
• View M&A activity and major deals
• Gain an understanding of the regulatory environment for the sector in China.
• Build a clear picture of trends, output and consumption for specific sub-sectors